HTML Microdata document

This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/chebi/
n6	http://linked.opendata.cz/resource/mesh/concept/
n14	http://linked.opendata.cz/resource/drugbank/company/
foaf	http://xmlns.com/foaf/0.1/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/wikipedia/
n21	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/pharmgkb/
n20	http://bio2rdf.org/drugbank:
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/kegg-compound/
adms	http://www.w3.org/ns/adms#
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/kegg-drug/
n10	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00890/identifier/drugbank/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n8	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7	http://linked.opendata.cz/ontology/drugbank/
owl	http://www.w3.org/2002/07/owl#
n5	http://linked.opendata.cz/ontology/mesh/
n11	http://linked.opendata.cz/resource/drugbank/property/
n4	http://www.rxlist.com/cgi/generic2/
xsdh	http://www.w3.org/2001/XMLSchema#
n13	http://linked.opendata.cz/resource/atc/
n12	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00890
rdf:type: n7:Drug
n7:description: Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis).
n7:group: approved
n7:indication: For use in the treatment of atrophic vaginitis and kraurosis vulvae.
n7:manufacturer: n14:271B5919-363D-11E5-9242-09173F13E4C5 n14:271B591B-363D-11E5-9242-09173F13E4C5 n14:271B591A-363D-11E5-9242-09173F13E4C5
owl:sameAs: n10:DB00890 n20:DB00890
dcterms:title: Dienestrol
adms:identifier: n16:C08090 n17:D00898 n18:DB00890 n19:4518 n21:PA164745534 n22:Dienestrol
n7:mechanismOfAction: Dienestrol is a synthetic, non-steroidal estrogen. Estrogens passively diffuse into target cells of responsive tissues, complex with the estrogen receptors, and enter the cell's nucleus to initiate or enhance gene transcription of protein synthesis after binding to DNA.
n7:packager: n14:271B5918-363D-11E5-9242-09173F13E4C5
n7:synonym: Dienestrolum Dehydrostilbestrol DV Diènestrol Dienestrol
n7:toxicity: Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
n7:proteinBinding: 50 to 80%
n7:synthesisReference: Short, W.F. and Hobday, G.1; U.S. Patent 2,464,203; March 15,1949; assigned to Boots Pure Drug Company Limited, England. Adler, E.; U.S. Patent 2,465,505; March 29,1949; assigned to Hoffmann-La Roche Inc.
n5:hasConcept: n6:M0006320
foaf:page: n4:diene.htm
n7:IUPAC-Name: n11:271B5921-363D-11E5-9242-09173F13E4C5
n7:InChI: n11:271B5927-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula: n11:271B5926-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight: n11:271B5923-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight: n11:271B5924-363D-11E5-9242-09173F13E4C5
n7:SMILES: n11:271B5925-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility: n11:271B591F-363D-11E5-9242-09173F13E4C5 n11:271B5937-363D-11E5-9242-09173F13E4C5
n7:logP: n11:271B5920-363D-11E5-9242-09173F13E4C5 n11:271B591D-363D-11E5-9242-09173F13E4C5 n11:271B5939-363D-11E5-9242-09173F13E4C5
n7:logS: n11:271B591E-363D-11E5-9242-09173F13E4C5 n11:271B593A-363D-11E5-9242-09173F13E4C5
n12:hasATCCode: n13:G03CC02 n13:G03CB01
n7:H-Bond-Acceptor-Count: n11:271B592D-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count: n11:271B592E-363D-11E5-9242-09173F13E4C5
n7:InChIKey: n11:271B5928-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-: n11:271B5929-363D-11E5-9242-09173F13E4C5
n7:Polarizability: n11:271B592B-363D-11E5-9242-09173F13E4C5
n7:Refractivity: n11:271B592A-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count: n11:271B592C-363D-11E5-9242-09173F13E4C5
n7:absorption: Systemic absorption and mode of action of dienestrol are undetermined.Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
n7:affectedOrganism: Humans and other mammals
n7:casRegistryNumber: 84-17-3
n7:category
n7:containedIn: n8:271B591C-363D-11E5-9242-09173F13E4C5
n7:Bioavailability: n11:271B5933-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter: n11:271B5935-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule: n11:271B5936-363D-11E5-9242-09173F13E4C5
n7:Melting-Point: n11:271B5938-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings: n11:271B5932-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge: n11:271B5931-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five: n11:271B5934-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name: n11:271B5922-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-: n11:271B592F-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-: n11:271B5930-363D-11E5-9242-09173F13E4C5